1652 Stock Overview
An investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Fusen Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.29 |
| 52 Week High | HK$1.20 |
| 52 Week Low | HK$0.24 |
| Beta | 0.37 |
| 1 Month Change | 0% |
| 3 Month Change | -64.20% |
| 1 Year Change | -72.90% |
| 3 Year Change | -73.15% |
| 5 Year Change | -91.71% |
| Change since IPO | -88.58% |
Recent News & Updates
Benign Growth For Fusen Pharmaceutical Company Limited (HKG:1652) Underpins Stock's 42% Plummet
Feb 12
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price
Dec 18Recent updates
Benign Growth For Fusen Pharmaceutical Company Limited (HKG:1652) Underpins Stock's 42% Plummet
Feb 12There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price
Dec 18Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns
Mar 06We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide
Feb 08
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 18Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition
Dec 07If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns
Nov 20Shareholder Returns
| 1652 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 13.7% | 1.7% | -0.7% |
| 1Y | -72.9% | 5.9% | 28.8% |
Return vs Industry: 1652 underperformed the Hong Kong Pharmaceuticals industry which returned 5.9% over the past year.
Return vs Market: 1652 underperformed the Hong Kong Market which returned 28.8% over the past year.
Price Volatility
| 1652 volatility | |
|---|---|
| 1652 Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 14.6% |
| 10% least volatile stocks in HK Market | 3.3% |
Stable Share Price: 1652's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1652's weekly volatility has increased from 9% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 1,140 | Dudu Cao | www.fusenyy.com |
Fusen Pharmaceutical Company Limited, an investment holding company, researches and develops, manufactures, and sells pharmaceutical products in the People’s Republic of China. The company’s product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; heat-clearing and detoxicating oral solutions; nicardipine hydrochloride injections; and other products. It also offers cardio cerebrovascular, blood pressure and sugar reduction, tonifying, qi-regulating, anti-anemia, antibacterial and anti-inflammatory, gastrointestinal tract, and expectorant cough category products.
Fusen Pharmaceutical Company Limited Fundamentals Summary
| 1652 fundamental statistics | |
|---|---|
| Market cap | HK$214.40m |
| Earnings (TTM) | -HK$96.16m |
| Revenue (TTM) | HK$456.26m |
0.5x
P/S Ratio-2.2x
P/E RatioIs 1652 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1652 income statement (TTM) | |
|---|---|
| Revenue | CN¥425.49m |
| Cost of Revenue | CN¥199.23m |
| Gross Profit | CN¥226.26m |
| Other Expenses | CN¥315.93m |
| Earnings | -CN¥89.67m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | -0.12 |
| Gross Margin | 53.18% |
| Net Profit Margin | -21.08% |
| Debt/Equity Ratio | 67.0% |
How did 1652 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 01:18 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fusen Pharmaceutical Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.